88 results found.
        
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
SeaSpine Reports 3Q18 Revenue of $35.8MM, +12.9% vs. 3Q17
SeaSpine picks up momentum, posts 3Q18 revenue of US $35.8MM, +12.9% vs. 3Q17.
SeaSpine Prices $50MM Public Offering of Stock
SeaSpine closed its underwritten public offering of 3,250,000 shares of its common stock for US $15.50/share, for gross proceeds of ~$50.4MM.
SeaSpine Launches Regatta Lateral System
SeaSpine commenced limited launch of the Regatta™ lateral interbody fusion system.
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Spine Market Growth Expected to Remain at 2%
By Carolyn LaWell Spine accounts for 18% of the orthopaedic industry’s overall revenue. In 2017, estimated sales of spine products (excluding biologics) exceeded $9 billion worldwide, an increase of 2.2% or $197 million vs. 2016, according to our estimates published in
SeaSpine 2Q18 Revenue +7% vs. 2Q17
SeaSpine announced 2Q18 revenue of US $36.4MM, +6.5% vs. 2Q17, and 1H18 revenue of $69.6MM, +5.3% vs. 1H17. Thi...
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
SeaSpine 1Q18 Revenue Grows 4% YoY
SeaSpine announced 1Q18 revenue of US $33.2MM, +4.1% vs. 1Q17.
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
SeaSpine Announces 4Q17, 2017 Revenue
SeaSpine announced 4Q17 revenue of US $34.0MM, +4.5% vs. 4Q16, and 2017 revenue of $131.8MM, +2.3% vs. 2016...
SeaSpine Expands Ventura NanoMetalene Range
SeaSpine expanded the Ventura™ NanoMetalene® interbody line to include sizes that accommodate a larger...
Recapping Your Predictions: Consolidations and Launches as Growth Opportunities
At the dawn of 2017, we published results of an ORTHOWORLD Membership survey in ORTHOKNOW. Among the questions, we asked you to predict: In 2017, where do the opportunities lie for you and your company? Your responses included new product launches; patient-specific implants and instrume...
SeaSpine Preliminary 4Q and 2017 Revenue
SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue ran...
The Orthopaedic Products and Services of 2017
By Julie A. Vetalice The annual rundown of products and services is like attending a reunion—we’re looking back over the year and keeping you informed on what everyone is doing. Here’s what made headlines with market entry in 2017. We’ll start with services, and ...
SeaSpine Gains FDA Clearance for OsteoBallast DBM in Resorbable Mesh
SeaSpine received FDA 510(k) clearance to market OsteoBallast™ Demineralized Bone Matrix...
Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance
By Julie A. Vetalice Looking at 3Q17 revenue and reading call transcripts, much was said about unforeseen headwinds that crept in before the close of the year, affecting orthopaedic companies in a variety of ways. Following weather events, oft-cited “softness&rdqu...
SeaSpine Reports 3Q17 Revenue
SeaSpine announced 3Q17 revenue of US $31.7MM, flat vs. 3Q16, and YTD revenue of $97.8MM, +1.6% vs. the prior year...
SeaSpine's Limited Launch of OsteoStrand Demineralized Bone Fibers
SeaSpine commenced limited launch of OsteoStrand™ Demineralized Bone Fibers, for use i...
SeaSpine Reports Preliminary 3Q17 Revenue
SeaSpine announced preliminary 3Q17 revenue of US $31.7MM, flat vs. 3Q16.
SeaSpine Launches Shoreline Anterior Cervical Standalone System
SeaSpine commenced full commercial launch of Shoreline®, its anterior cervical standalone system
Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report
By Julie A. Vetalice Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With now just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.
SeaSpine Posts 2Q17 Revenue
SeaSpine announced 2Q17 revenue of US $34.2MM, +3.0% vs. 2Q16, and 1H17 revenue of $66.1MM, +2.3% vs. 1H16.
SeaSpine Introduces Skipjack Expandable Interbody System
SeaSpine commenced limited launch and announced initial case completion for the Skipjack™
SeaSpine Reports Preliminary 2Q17 Revenue
SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16.
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2018 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group